Skoulidis F, Arbour KC, Hellmann MD, Patil P, Marmarelis ME, Owen D, Swad MM, Murray J, Levy B, Hellyer J, Gainor JF, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings AL, Elamin YY, Lam VK, Zhang J, Shu CA, Riess JW, B lakely C Pecot C, Mezquita L, Tabbo F, Sacher A, Scheffler M, Bicciuti B, Venkatraman D, Rizvi H, Liu C Johnston RP, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Laroix L, Memmott RM, Madrigal JR, Goldman JW, Lau S, Carter B, Woodcock M, Roth JA, Swisher SG , Leighl N, Wolf J, Scagliotti GV, Planchard D, Besse B, Bivona T, Gandara DR, Garon EB, Rizvi N, Camidge R, Schalper K, Herbst RS, Shaw A, Neal J, Wakelee HA, Brahmer J, Janne P, Carbone DP, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach JV
poor reporting of randomization and allocation concealment, leading to selection bias
412 In an additional study, benzbromarone demonstrated a lower risk of experiencing the initial gout flare and developing type 2 diabetes when contrasted with allopurinol
S2 Table contains raw mRNA read counts for each tissue and rat across both genotypes
4 Materials and methods 4.1 Cell culture and in vivo experiments 4.1.1 Cell lines Four human NB cell lines were used in this paper: Be(2)-C (MNA), IMR5-/75-shMYCN (29) (MNA, doxycycline-inducible shRNA targeting MYCN, resulting in MYCN downregulation), IMR-32 (MNA), and SH-SY5Y/6TR(EU)/pTrex-Dest-30/MYCN (non-MNA, doxycycline-inducible transgene, resulting in MYCN overexpression)
P = 001) (online Supplementary Fig
